Nashik’s 13 Were Part of DRDO Trial for 2-DG Drug | Nashik News


Nashik: Up to 13 Covid-19 patients from Nashik participated in the phase III trial of the drug DRDO at a private hospital in the city.
The private hospital in Nashik was chosen for the testing of a drug developed by DRDO’s main laboratory, the Institute of Nuclear Medicine and Allied Sciences (INMAS), in collaboration with private laboratories.
The drug (2-DG) has now obtained emergency use approval from the Comptroller General of Medicines of India (DGCI) to help reduce reliance on supplemental oxygen.
Explaining the process of the trial, Dr Manoj Chopda, MD (internal medicine) and DM (cardiologist) from the private hospital, said patients needing oxygen or ventilators were chosen for the trial with permission from their family and after informing them of the problems related to the disease. trial.
“Eight men and five women were chosen for the trial and all were between 45 and 70 years old. All of the patients described faster recovery in terms of oxygen use as well as testing negative for Covid, ”he said.
“We observed the patients for 14 days with a minimum hospital stay of seven days. The significant finding of the same was that the drug helped drastically reduce the need for supplemental oxygen, ”he added.
While the non-oxygen patients tested negative for the virus on the eighth day, those on oxygen did not need any assistance in breathing after the third day of treatment.
“At the same time, patients on BiPAP (two-level positive airway pressure) were put on oxygen and once saturation was stable they were also removed from oxygen,” Chopda said, adding that the patient stay time was significantly reduced.

About Hector Hedgepeth

Check Also

Collaborate with academia for drug discovery targeting immune-mediated diseases

By George Vratsanos, MD, and Luke Devey, MD, Ph.D., Janssen Immunology There are many critical …

Leave a Reply

Your email address will not be published.